Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Table 3 Clinical information of high and low protein tyrosine phosphatase non-receptor 2 expression groups of patients from the Bengbu Medical College database

Characteristic	Total (n)	PTPN2 expression		χ2	P value
		Low (n = 41)	High (n = 85)
Sex, n (%)
Female	23	5 (3.9)	18 (14.3)	1.495	0.221
Male	103	36 (28.6)	67 (53.2)
Age
≤ 65 years	91	32 (25.4)	59 (46.8)	1.028	0.311
> 65 years	35	9 (7.2)	26 (20.6)
Viral hepatitis, n (%)
Yes	110	35 (27.8)	75 (59.5)	0.205	0.651
No	16	6 (4.8)	10 (7.9)
Liver cirrhosis, n (%)
Yes	61	20 (15.9)	41 (32.5)	0.003	0.956
No	65	21 (16.7)	44 (34.9)
AFP (ng/mL), n (%)
≤ 25	52	24 (19.0)	32 (25.4)	4.888	0.027
> 25	74	17 (14.5)	53 (42.1)
Tumor size, n (%)
≤ 5 cm	65	23 (18.3)	42 (33.3)	0.495	0.482
> 5 cm	61	18 (14.3)	43 (34.1)
Degree of differentiation, n (%)
Undifferentiated	29	7 (5.6)	22 (17.5)	1.324	0.516
Moderately differentiated	76	26 (20.6)	50 (39.7)
Highly differentiated	21	8 (6.3)	13 (10.3)

PTPN2: Protein tyrosine phosphatase non-receptor 2; AFP: α-fetoprotein.